Renalytix (RENX): Fundraise and debt conversion

This situation live

£36m · 6.0p · +45% since the first step

1 Sep 2026 · Bookbuild open; first tranche admission expected 7 September · +0% until the next step It is expected that the General Meeting will be held in late -September 2026.

3 Sep 2026 · Retail offer open; first tranche admission pending · +45% since The WRAP Retail Offer is expected to close at 4:00 p.m. on 7 September 2026.

Dilutive fundraise

Fundraise and debt conversion

Retail offer open; first tranche admission pending

Every step · 3

1 Sep 2026 Bookbuild open; first tranche admission expected 7 September – It is expected that the General Meeting will be held in late -September 2026. ↗
3 Sep 2026 Bookbuild closed oversubscribed; first tranche admission pending – The first tranche of the Fundraise will now complete and the issue of the 57,729,741 Conversion Shares to HCM and the 109,082,253 First Tranche Placing... ↗
3 Sep 2026 Retail offer open; first tranche admission pending – The WRAP Retail Offer is expected to close at 4:00 p.m. on 7 September 2026. ↗

What is happening

Renalytix: Fundraise and debt conversion – Retail offer open; first tranche admission pending. ['Retail offer open; first tranche admission pending']

In short: Renalytix launched a bookbuild on 1 September 2026 at 6p, a premium to the market price. It funds the Quest Diagnostics rollout and converts the Heights bonds to equity. The bookbuild closed oversubscribed with £10.1m raised, and Heights holds no debt claim. A WRAP retail offer of up to £1.0m at 6p now opens, closing 7 September. The second tranche needs a General Meeting.
Announced: 1 Sep 2026 · Bookbuild open; first tranche admission expected 7 September
Latest: 3 Sep 2026 · Retail offer open; first tranche admission pending
Size: £10.1m gross placing at 6p; up to £1.0m WRAP Retail Offer
Shares: 168,366,151 new shares plus 57,729,741 Conversion Shares to Heights
First tranche: 109,082,253 Placing Shares plus 57,729,741 Conversion Shares; admission 8 September 2026
Second tranche: Second Tranche Placing, Subscription and Retail Offer Shares; needs General Meeting; admission about 29 September 2026
Next milestone: Retail offer result expected on or around 8 September 2026
Insiders: Directors and PDMRs subscribed US$303,366 in total; 6-month lock-in
Price: 6p, a 44.6% premium to the 4.15p close on 28 August 2026
Retail offer: Up to 16,666,666 shares; minimum £100; closes 4:00 p.m. on 7 September 2026

Briefing Pro

What it does, how it got here, what management promised and delivered – written from its own announcements.

From the company's own announcements. Not investment advice.

Also at Renalytix 3 open